CAPG and urinary bladder carcinoma: We discovered SB525334 as a strong CAPG inhibitor in bladder cancer cells, potentially enhancing cisplatin's effectiveness by targeting CAPG.<h4>Conclusion</h4>Bladder cancer patients face an elevated CVD death risk due to high CAPG protein expression, which can raise serum CAPG levels and harm cardiomyocytes.